Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent

Cancer Research

Volumn 67, Issue 1, 2007, Pages 254-261

  Dennis, Mark S ^a   Jin, Hongkui ^a   Dugger, Debra ^a   Yang, Renhui ^a   McFarland, Leanne ^a   Ogasawara, Annie ^a   Williams, Simon ^a   Cole, Mary J ^a   Ross, Sarajane ^a   Schwall, Ralph ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALBUMIN BINDING IMMUNOGLOBULIN F(AB) 4D5 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) 4D5 FRAGMENT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MECHANISM; FEMALE; HISTOLOGY; KIDNEY; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VIRUS;

ALBUMINS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; RECEPTOR, ERBB-2;

EID: 33846404133     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2531     Document Type: Article

References (46)

1. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration and affinity for retention. Cancer Res 2003;63:1288-96.
2. Jain RK. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J Control Release 2001;74:7-25.
3. Zuckier LS, Berkowitz EZ, Sattenberg RJ, Zhao QH, Deng HF, Scharff MD. Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. Cancer Res 2000:60:7008-13.
4. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Methods 1999;231:249-60.
5. Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Hudson PJ. Effects of genetic engineering on the therapy and pharmacokinetics of antibodies. QJ Nucl Med 1999;43:132-9.
6. Kashmiri SVS. Multivalent single-chain antibodies for radioimaging of tumors. J Nucl Med 2001;42:1528-9.
7. Li Q, Hudson W, Wang D, Berven E, Uckum FM, Kersey JH. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy. Cancer Immunol Immunother 1998'47:121-30.
8. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-71.
9. Rowlinson-Busza G, Deonarain MP, Epenetos AA. Comparison of intact monoclonal antibody, its F(ab')2 and Fab fragments and recombinant single chain Fv in a human tumor xenograft model. Tumor Target 1996;2:37-48.
10. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996;2:21-36.
11. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
12. Mach JP, Pelegrin A, Buchegger F. Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol 1991;3:685-93.
13. Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995;38:126-42.
14. Stehle G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and genesis of cachexia. Crit Rev Oncol Hematol 1997;26:77-100.
15. Wunder A, Stehle G, Sinn H, et al. Enhanced albumin uptake by rat tumors. Int J Oncol 1997;11:497-507.
16. Burger AM, Hartung G, Stehle G, Sinn H, Fiebig HH. Pre-clinical evaluation of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts in vivo. Int J Cancer 2001;92:718-24.
17. Kratz F, Muller-Driver R, Hofmann I, Drevs J, Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000;43:1253-6.
18. Wosikowski K, Biedermann E, Rattel B, et al. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells. Clin Cancer Res 2003;9:1917-26.
19. Dennis MS, Zhang M, Meng YG, et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002;277:35035-43.
20. Nguyen A, Reyes AE II, Zhang M, et al. The pharmacokinetics of an albumin binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 2006;19:291-7.
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001;344:783-92.
22. Carter P, Presta LG, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285.
23. Kelley RF, O'Connell MP, Carter P, et al. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody fragments. Biochemistry 1992;31:5434-41.
24. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992;52:6553-60.
25. Carter P, Kelley RF, Rodrigues ML, et al. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 1992;10:163-7.
26. Finkle D, Quan ZR, Asghari V, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHEH2-transgenic mice. Clin Cancer Res 2004;10:2499-511.
27. Jain RK. Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin Cancer Res 1999;5:1605-6.
28. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting or ErbB2 and the site of action of cancer therapeutics Trastuzumab and Geldanamycin. Mol Biol Cell 2004;15:5268-82.
29. Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: Analysis of biophysical mechanisms. Biophys J 2003;85:2732-45.
30. Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1999;42:225-41.
31. Pavlinkova G, Beresford GW, Booth BJM, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999;40:1536-46.
32. Smith-Jones PM, Solit DB, Akhurst T, Afoze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
33. Williams LE, Wu AM, Yazaki PJ, et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radiopharm 2001;16:25-35.
34. Verhaar MJ, Chester KA, Keep PA, et al. A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma. Int J Cancer 1995;61:497-501.
35. Kobayashi H, Shirakawa K, Kawamoto S, et al. Rapid accumulation and internalization of radiolabeled Herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MR1 with the macromolecular contrast agent G6-(1B4M-Gd)256. Cancer Res 2002;62:860-6.
36. Tsai SW, Sun YY, Williams LE, Raubitschek AA, Wu AM, Shively JE. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5. Bioconjug Chem 2000;11:327-34.
37. De Santes K, Slamon D, Anderson SK, et al. Radiolabeled antibody targeting of the HER2/neu oncoprotein. Cancer Res 1992;52:1916-23.
38. IIIIn- trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005;32:51-8.
39. IIIIn-DTPA-trastuzumab. Br J Pharmacol 2004;143:99-106.
40. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach J-P. Penetration and binding of radiolabeled anticarcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987;47:1627-33.
41. Krol A, Maresca J, Dewhirst MW, Yuan F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res 1999;59:4136-41.
42. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43.
43. Chaudhury C, Mehnaz S, Robinson JM, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 2003;197:315-22.
44. Minshall RD, Tiruppathi C, Vogel SM, Malik AB. Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol 2002;117:105-12.
45. Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60 and microvascular endothelium. Am J Physiol 1992;263:H1872-9.
46. Tiruppathi C, Naqvi T, Wu Y, Vogel SM, Minshall RD, Malik AB. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci U S A 2004;101:7699-704.